{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T15:18:21Z","timestamp":1784647101314,"version":"3.55.0"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Background and aim<\/jats:title><jats:p>Wilson\u2019s disease (WD), an autosomal recessive copper metabolism defect, causes pathological copper deposition in hepatic and neurological systems, culminating in cirrhosis and neuropsychiatric manifestations. Our understanding of neurological deterioration in neurological WD patients following sodium dimercaptopropanesulfonate (DMPS) treatment is limited. Thus, this study aims to analyze the phenotypic spectrum and predictors of DMPS-induced neurological deterioration in neurological WD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Demographic (age, gender, weight), clinical (K-F ring, duration of illness), and biochemical parameters [alanine aminotransferase, aspartate aminotransferase, albumin, serum ceruloplasmin, blood urea nitrogen, serum creatinine, 24\u202fh urinary copper, lactate, homocysteine (HCY)] were systematically evaluated alongside neuroimaging data, followed by receiver operating characteristic (ROC) curve analysis to identify predictive biomarkers for neurological deterioration in DMPS-induced neurological WD patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 277 neurological WD patients were enrolled, among whom 24.5% (68\/277) developed neurological deterioration. Notably, 70.6% (48\/68) of the patients experiencing neurological worsening were male. Among the patients, 91.2% (62\/68) exhibited mild deterioration, while 8.8% (6\/68) experienced severe deterioration. Multivariate logistic regression analysis indicated that sex [odds ratio (OR)\u202f=\u202f0.41[95% confidence interval (CI)\u202f=\u202f0.18\u20130.94], <jats:italic>p<\/jats:italic>\u202f=\u202f0.035], brain Magnetic Resonance Imaging (MRI) score (OR\u202f=\u202f2.89[95% CI\u202f=\u202f1.99\u20134.21], <jats:italic>p<\/jats:italic>\u202f&amp;lt;\u202f0.001), and HCY (OR\u202f=\u202f1.45[95% CI\u202f=\u202f1.27\u20131.65], <jats:italic>p<\/jats:italic>\u202f&amp;lt;\u202f0.001) were associated with neurological deterioration. Subgroup analysis revealed statistically significant differences in male proportion (36\/19 vs. 75\/84, <jats:italic>p<\/jats:italic>\u202f=\u202f0.019), brain MRI score (median: 5 vs. 4, <jats:italic>p<\/jats:italic>\u202f&amp;lt;\u202f0.001), and HCY levels (mean: 20.75 vs. 17.77, <jats:italic>p<\/jats:italic>\u202f&amp;lt;\u202f0.001) between the deterioration and non-deterioration groups within the under-35 cohort. ROC analysis of composite biomarkers demonstrated significant predictive capacity for neurological deterioration in DMPS-induced neurological WD (AUC\u202f=\u202f0.862).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Neurological deterioration in DMPS-induced neurological WD patients is not rare and predominantly occurs in males. We identified three independent risk factors for this deterioration: sex, brain MRI score, and HCY. A composite risk model incorporating these parameters achieved superior predictive accuracy compared to individual biomarker.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2025.1599209","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T04:14:06Z","timestamp":1759119246000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["DMPS-induced neurological deterioration in neurological Wilson\u2019s disease patients: a retrospective case-control study on clinical characteristics and risk factors"],"prefix":"10.3389","volume":"16","author":[{"given":"Yannan","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lulu","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shupei","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guran","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenming","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1017\/s0317167100017315","article-title":"Wilson disease in the south Chinese Han population","volume":"41","author":"Cheng","year":"2014","journal-title":"Can J Neurol Sci"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1080\/14737175.2023.2268841","article-title":"Tackling the neurological manifestations in Wilson's disease - currently available treatment options","volume":"23","author":"Litwin","year":"2023","journal-title":"Expert Rev Neurother"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.ncl.2020.01.005","article-title":"Wilson disease: an overview and approach to management","volume":"38","author":"Mulligan","year":"2020","journal-title":"Neurol Clin"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/b978-0-444-63625-6.00018-5","article-title":"Symptomatic treatment of neurologic symptoms in Wilson disease","volume":"142","author":"Litwin","year":"2017","journal-title":"Handb Clin Neurol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1007\/s13760-022-02091-z","article-title":"Serum neurofilament light chain and initial severity of neurological disease predict the early neurological deterioration in Wilson's disease","volume":"123","author":"Ziemssen","year":"2023","journal-title":"Acta Neurol Belg"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1186\/s12883-020-01827-9","article-title":"Combined sodium Dimercaptopropanesulfonate and zinc versus D-penicillamine as first-line therapy for neurological Wilson's disease","volume":"20","author":"Zhang","year":"2020","journal-title":"BMC Neurol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1177\/1756285616641598","article-title":"Clinical efficacy of combined sodium dimercaptopropanesulfonate and zinc treatment in neurological Wilson's disease with D-penicillamine treatment failure","volume":"9","author":"Chen","year":"2016","journal-title":"Ther Adv Neurol Disord"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1034\/j.1600-0676.2003.00824.x","article-title":"Diagnosis and phenotypic classification of Wilson disease","volume":"23","author":"Ferenci","year":"2003","journal-title":"Liver Int"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"BSR20200654","DOI":"10.1042\/bsr20200654","article-title":"Combined dimercaptosuccinic acid and zinc treatment in neurological Wilson's disease patients with penicillamine-induced allergy or early neurological deterioration","volume":"40","author":"Zhu","year":"2020","journal-title":"Biosci Rep"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1136\/gut.2005.087262","article-title":"Clinical presentation, diagnosis and long-term outcome of Wilson's disease: a cohort study","volume":"56","author":"Merle","year":"2007","journal-title":"Gut"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1097\/NMD.0b013e3182a2168a","article-title":"Diagnostic and statistical manual of mental disorders, 5th edition, and clinical utility","volume":"201","author":"First","year":"2013","journal-title":"J Nerv Ment Dis"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"e3170","DOI":"10.1002\/brb3.3170","article-title":"Symptom aggravation after withdrawal of metal chelating agent therapy in patients with Wilson's disease","volume":"13","author":"Zhou","year":"2023","journal-title":"Brain Behav"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"875694","DOI":"10.3389\/fgene.2022.875694","article-title":"Clinical and genetic analysis in neurological Wilson's disease patients with neurological worsening following Chelator therapy","volume":"13","author":"Hou","year":"2022","journal-title":"Front Genet"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s11596-013-1190-z","article-title":"Clinical efficacy and safety of chelation treatment with typical penicillamine in cross combination with DMPS repeatedly for Wilson's disease","volume":"33","author":"Xu","year":"2013","journal-title":"J Huazhong Univ Sci Technolog Med Sci"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12015\/issn.1674-8034.2021.03.001","article-title":"Clinical and MRI analysis of hepatic and cerebral hepatolenticular degeneration Chinese","volume":"12","author":"Zhao","year":"2021","journal-title":"J Magn Reson Imaging"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"37","DOI":"10.5334\/tohm.794","article-title":"Clinical spectrum, radiological correlation and outcome of movement disorders in Wilson's disease","volume":"13","author":"Mahale","year":"2023","journal-title":"Tremor Other Hyperkinet Mov (N Y)"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1002\/mds.28018","article-title":"Semiquantitative scale for assessing brain MRI abnormalities in Wilson disease: a validation study","volume":"35","author":"Dusek","year":"2020","journal-title":"Mov Disord"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1176946","DOI":"10.3389\/fneur.2023.1176946","article-title":"Role of gender and age in features of Wilson's disease","volume":"14","author":"Cai","year":"2023","journal-title":"Front Neurol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.3390\/ijms24043205","article-title":"Is hormone replacement therapy a risk factor or a therapeutic option for Alzheimer's disease?","volume":"24","author":"Mills","year":"2023","journal-title":"Int J Mol Sci"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1210\/er.2016-1007","article-title":"Estrogens, neuroinflammation, and neurodegeneration","volume":"37","author":"Villa","year":"2016","journal-title":"Endocr Rev"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13293-025-00692-w","article-title":"Sex and gender differences in the molecular etiology of Parkinson's disease: considerations for study design and data analysis","volume":"16","author":"Schaffner","year":"2025","journal-title":"Biol Sex Differ"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.jhep.2023.04.007","article-title":"Neurological worsening in Wilson disease - clinical classification and outcome","volume":"79","author":"Mohr","year":"2023","journal-title":"J Hepatol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"698","DOI":"10.4103\/aian.aian_519_21","article-title":"Management of Children and Adolescents with Wilson disease and neurological worsening following D-Penicillamine therapy: a single Centre experience","volume":"25","author":"Kumar","year":"2022","journal-title":"Ann Indian Acad Neurol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1002\/mdc3.13547","article-title":"Brain MRI in the decision for liver transplantation in pediatric neurological Wilson's disease","volume":"9","author":"Pinto","year":"2022","journal-title":"Mov Disord Clin Pract"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1136\/jnnp-2021-326123","article-title":"Wilson's disease: update on pathogenesis, biomarkers and treatments","volume":"92","author":"Shribman","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1146644","DOI":"10.3389\/fnins.2023.1146644","article-title":"Microstructural and functional impairment of the basal ganglia in Wilson's disease: a multimodal neuroimaging study","volume":"17","author":"Su","year":"2023","journal-title":"Front Neurosci"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.jns.2015.06.010","article-title":"Early neurological worsening in patients with Wilson's disease","volume":"355","author":"Litwin","year":"2015","journal-title":"J Neurol Sci"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1177\/1756283x17731520","article-title":"Insights into the management of Wilson's disease","volume":"10","author":"Kathawala","year":"2017","journal-title":"Ther Adv Gastroenterol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.jhep.2011.11.007","article-title":"EASL clinical practice guidelines: Wilson's disease","volume":"56","year":"2012","journal-title":"J Hepatol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"3749","DOI":"10.1007\/s10072-020-04973-7","article-title":"Study on different pathogenic factors in different disease stages of patients with Wilson disease","volume":"42","author":"Zhou","year":"2021","journal-title":"Neurol Sci"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/s1474-4422(14)70190-5","article-title":"Wilson's disease and other neurological copper disorders","volume":"14","author":"Bandmann","year":"2015","journal-title":"Lancet Neurol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.3969\/j.issn.1673-4130.2018.14.026","article-title":"Clinical significance and progress of detection methods for serum free copper detection in Wilson disease","volume":"39","author":"Sun","year":"2018","journal-title":"Int J Lab Med"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"4405","DOI":"10.1007\/s10072-022-06001-2","article-title":"Brain magnetic resonance imaging and severity of neurological disease in Wilson's disease - the neuroradiological correlations","volume":"43","author":"R\u0119dzia-Ogrodnik","year":"2022","journal-title":"Neurol Sci"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1007\/s00775-019-01737-3","article-title":"Copper and the brain noradrenergic system","volume":"24","author":"Lutsenko","year":"2019","journal-title":"J Biol Inorg Chem"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1111\/j.1749-6632.2009.05109.x","article-title":"Neurologic Wilson's disease","volume":"1184","author":"Lorincz","year":"2010","journal-title":"Ann N Y Acad Sci"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s11011-013-9378-2","article-title":"The effect of gender on brain MRI pathology in Wilson's disease","volume":"28","author":"Litwin","year":"2013","journal-title":"Metab Brain Dis"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1046\/j.1468-1331.2003.00661.x","article-title":"MR imaging of the brain in patients with hepatic form of Wilson's disease","volume":"10","author":"Kozi\u0107","year":"2003","journal-title":"Eur J Neurol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"133","DOI":"10.2217\/nmt-2015-0008","article-title":"The relationship between hyperhomocysteinemia and neurodegeneration","volume":"6","author":"Bonetti","year":"2016","journal-title":"Neurodegener Dis Manag"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.neuint.2016.10.001","article-title":"Oxidative stress and mitochondrial dysfunction are the underlying events of dopaminergic neurodegeneration in homocysteine rat model of Parkinson's disease","volume":"101","author":"Bhattacharjee","year":"2016","journal-title":"Neurochem Int"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3390\/ijms21207698","article-title":"Homocysteine and mitochondria in cardiovascular and cerebrovascular systems","volume":"21","author":"Kaplan","year":"2020","journal-title":"Int J Mol Sci"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1097\/meg.0000000000002801","article-title":"Analysis of risk factors for fatty liver disease in children with Wilson's disease","volume":"36","author":"Jia","year":"2024","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"3854","DOI":"10.1093\/hmg\/ddy262","article-title":"Epigenetic changes of the thioredoxin system in the tx-j mouse model and in patients with Wilson disease","volume":"27","author":"Mordaunt","year":"2018","journal-title":"Hum Mol Genet"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1599209\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T04:14:08Z","timestamp":1759119248000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1599209\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":42,"alternative-id":["10.3389\/fneur.2025.1599209"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2025.1599209","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,29]]},"article-number":"1599209"}}